Immune checkpoint inhibitors are the standard of care for second-line treatment in advanced NSCLC, and pembrolizumab should be considered a standard first-line treatment in NSCLC patients with a good PS whose tumors have PD-L1 expression ≥50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.